EUVIMEDEUVIMED entdecken
Crossref

The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B‐cell precursor acute lymphoblastic leukaemia in measurable residual disease‐negative remission

Jose Tinajero iD, Dat Ngo iD, Maria Motta, Vaibhav Agrawal iD, Paul Koller iD, Hoda Pourhassan iD, Lindsey Murphy iD, Shukaib Arslan iD, Stephen Forman, Anthony Stein, Guido Marcucci, Vinod Pullarkat und 1 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.20200 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Jose Tinajero und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, City of Hope, Duarte, California, USA. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Consolidation Chemotherapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Blinatumomab consolidation was recently approved for patients with acute lymphoblastic leukaemia (ALL) who achieve measurable residual disease (MRD) negative remission based on the survival benefit yielded in the E1910 trial. The CALGB 10403 (C10403) is the most frequently used paediatric inspired regimen for young adults treated in the United States; however, data and guidance on how to best incorporate blinatumomab consolidation into the C10403 regimen are lacking. Here, we describe our experience of adding blinatumomab consolidation to the C10403 regimen per our institutional consensus. Thirty‐one adult patients met inclusion criteria. The median age was 31 years and the majority were males (64.5%) and Hispanic (83.9%). The most common ALL subtype was Philadelphia‐like (45.2%). The median follow‐up was 13.7 months and the median overall survival was not reached (NR) (95% confidence interval [CI] NR–NR) with one death occurring post allogenic transplant and one relapse (3.2%). All‐grade cytokine release syndrome and treatment‐related neurological/psychiatric adverse event rates were 9.7% and 19.4%, respectively, and none of the patients permanently discontinued blinatumomab due to toxicity. The majority (84.6%) of patients were able to receive over half of their planned pegaspargase doses. The incorporation of blinatumomab consolidation to C10403 is safe and feasible in adults with ALL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificPrecursor B-Cell Lymphoblastic Leukemia-LymphomaConsolidation ChemotherapyAntineoplastic Combined Chemotherapy ProtocolsHumansMaleAdultFemaleNeoplasm, ResidualMiddle AgedYoung AdultRemission InductionAdolescent

Stichwörter der Autor:innen

CALGB 10403MRD negativeacute lymphoblastic leukaemiablinatumomabconsolidation

Substanzen

blinatumomabAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of Pharmacy, City of Hope, Duarte, California, USA.
  • Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
  • Department of Pediatrics, City of Hope, Duarte, California, USA.

ORCID-Profile: Jose Tinajero, Dat Ngo, Vaibhav Agrawal, Paul Koller, Hoda Pourhassan, Lindsey Murphy, Shukaib Arslan, Ibrahim Aldoss

Zitieren

APA

Tinajero, J., Ngo, D., Motta, M., Agrawal, V., Koller, P., Pourhassan, H., Murphy, L., Arslan, S., Forman, S., Stein, A., Marcucci, G., Pullarkat, V., & Aldoss, I. (2025). The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B‐cell precursor acute lymphoblastic leukaemia in measurable residual disease‐negative remission. British Journal of Haematology. https://doi.org/10.1111/bjh.20200

Vancouver

Tinajero J, Ngo D, Motta M, Agrawal V, Koller P, Pourhassan H, et al. The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B‐cell precursor acute lymphoblastic leukaemia in measurable residual disease‐negative remission. British Journal of Haematology. 2025. doi:10.1111/bjh.20200

BibTeX
@article{Tinajero2025,
  author = {Tinajero, Jose and Ngo, Dat and Motta, Maria and Agrawal, Vaibhav and Koller, Paul and Pourhassan, Hoda and Murphy, Lindsey and Arslan, Shukaib and Forman, Stephen and Stein, Anthony and Marcucci, Guido and Pullarkat, Vinod and Aldoss, Ibrahim},
  title = {The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B‐cell precursor acute lymphoblastic leukaemia in measurable residual disease‐negative remission},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.20200}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche